Table 4.
Risk of alcohol-related cirrhosis by diabetes status, and comparison of risk in the low- and high-risk of the 3-SNP score stratified by diabetes status. For GenomALC-1, diabetes status was at time of recruitment and for UK Biobank at the time of (baseline) assessment. Information on diabetes was not available for the GenomALC-2 group. Only those participants with information on diabetes, and a 3-SNP score, are included.
| Predictor | Group | Contrast | Odds Ratios (95% Confidence Intervals) | |
|---|---|---|---|---|
| GenomALC-1 | UK Biobank | |||
|
| ||||
| Diabetes | Diabetes versus no diabetes | 3.82 (2.67 to 5.47) | 5.62 (4.33 to 7.28) | |
|
| ||||
| 3-SNP score | No diabetes | ≤0 versus >0.7 in non-diabetics | 4.77 (3.45 to 6.58) | 2.37 (1.86 to 3.03) |
| Diabetes | ≤0 (diabetes) versus >0.7 (diabetes) | 5.32 (2.06 to 13.7)1 | 3.74 (2.16 to 6.48)2 | |
| ≤0 (no-diabetes) versus >0.7 (diabetes) | 14.7 (7.69 to 28.1) | 17.1 (11.3 to 25.7) | ||
1
Breslow-Day test for homogeneity of Odds Ratios in Non-Diabetes and Diabetes groups, GenomALC-1 χ2 = 0.05 p = 0.830.
2
Breslow-Day test for homogeneity of Odds Ratios in Non-Diabetes and Diabetes groups, UK Biobank χ2 = 2.20 p = 0.138.